Kamran Alam Biography and Net Worth

Mr. Kamran Alam is a Chief Financial Officer at Taysha Gene Therapies, Inc. Mr. Alam was previously employed as a Chief Financial Officer & Senior Vice President by Rocket Pharmaceuticals, Inc., a Vice President-Finance by AveXis, Inc., a Senior Director-Finance & Accounting by Aptinyx, Inc., and a Finance Director by Naurex, Inc. He received his undergraduate degree from Stephen M. Ross School of Business and an MBA from Kelley School of Business.

What is Kamran Alam's net worth?: The estimated net worth of Kamran Alam is at least $619,300.80 as of August 24th, 2023. Mr. Alam owns 258,042 shares of Taysha Gene Therapies stock worth more than $619,301 as of April 24th. This net worth approximation does not reflect any other investments that Mr. Alam may own. Additionally, Mr. Alam receives an annual salary of $703,610.00 as CFO at Taysha Gene Therapies. Learn More about Kamran Alam's net worth.
How old is Kamran Alam?: Mr. Alam is currently 46 years old. There are 2 older executives and no younger executives at Taysha Gene Therapies. Learn More on Kamran Alam's age.
What is Kamran Alam's salary?: As the CFO of Taysha Gene Therapies, Inc., Mr. Alam earns $703,610.00 per year. Learn More on Kamran Alam's salary.
How do I contact Kamran Alam?: The corporate mailing address for Mr. Alam and other Taysha Gene Therapies executives is 2280 Inwood Road, DALLAS TX, 75235. Taysha Gene Therapies can also be reached via phone at 214-612-0000 and via email at [email protected]. Learn More on Kamran Alam's contact information.
Has Kamran Alam been buying or selling shares of Taysha Gene Therapies?: Kamran Alam has not been actively trading shares of Taysha Gene Therapies within the last three months. Most recently, Kamran Alam sold 33,000 shares of the business's stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $2.33, for a transaction totalling $76,890.00. Following the completion of the sale, the chief financial officer now directly owns 258,042 shares of the company's stock, valued at $601,237.86. Learn More on Kamran Alam's trading history.
Who are Taysha Gene Therapies' active insiders?: Taysha Gene Therapies' insider roster includes Kamran Alam (CFO), Phillip Donenberg (Director), Paul Manning (Director), Sean Nolan (Director), and R.A. Session, II (CEO). Learn More on Taysha Gene Therapies' active insiders.
Are insiders buying or selling shares of Taysha Gene Therapies?: In the last twelve months, Taysha Gene Therapies insiders bought shares 5 times. They purchased a total of 17,405,000 shares worth more than $15,736,400.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 419,689 shares worth more than $351,334.11. The most recent insider tranaction occured on November, 17th when Major Shareholder Paul B Manning bought 100,000 shares worth more than $163,000.00. Insiders at Taysha Gene Therapies own 2.3% of the company. Learn More about insider trades at Taysha Gene Therapies.
Information on this page was last updated on 11/17/2023.

Kamran Alam Insider Trading History at Taysha Gene Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/24/2023	Sell	33,000	$2.33	$76,890.00	258,042
8/22/2022	Sell	9,717	$3.50	$34,009.50	269,446
8/18/2022	Sell	7,476	$3.87	$28,932.12	290,645
8/20/2021	Sell	11,840	$16.78	$198,675.20	319,928
8/18/2021	Sell	11,193	$17.35	$194,198.55	319,928

Kamran Alam Buying and Selling Activity at Taysha Gene Therapies

Taysha Gene Therapies Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Today's Range

Now: $2.40

$2.40

$2.54

50 Day Range

MA: $2.60

$1.46

$3.25

2 Week Range

Now: $2.40

$0.50

$3.89

Volume

240,061 shs

Average Volume

2,596,840 shs

Market Capitalization

$448.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

Kamran Alam Biography and Net Worth

What is Kamran Alam's net worth?

How old is Kamran Alam?

What is Kamran Alam's salary?

How do I contact Kamran Alam?

Has Kamran Alam been buying or selling shares of Taysha Gene Therapies?

Who are Taysha Gene Therapies' active insiders?

Are insiders buying or selling shares of Taysha Gene Therapies?